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Epigenetic modifications are those reversible, mitotically heritable alterations in genomic expression that occur
independent of changes in gene sequence. Epigenetic studies have the potential to improve our understanding of
the etiology of mood and anxiety disorders and suicide by bridging the gap in knowledge between the exogenous
environmental exposures and pathophysiology that produce common mood and anxiety disorders and suicide. We
systematically reviewed the English-language peer-reviewed literature about epigenetic regulation in these
disorders between 2001–2011, summarizing and synthesizing this literature with respect to directions for future
work. Twenty-one articles met our inclusion criteria. Twelve studies were concerned with epigenetic changes
among suicide completers; other studies considered epigenetic regulation in depression, post-traumatic stress
disorder, and panic disorder. Several studies focused on epigenetic regulation of amine, glucocorticoid, and
serotonin metabolism in the production of common mood and anxiety disorders and suicide. The literature is
nascent and has yet to reach consensus about the roles of particular epigenetic modifications in the etiology of
these outcomes. Future studies require larger sample sizes and measurements of environmental exposures
antecedent to epigenetic modification. Further work is also needed to clarify the link between epigenetic
modifications in the brain and peripheral tissues and to establish ‘gold standard’ epigenetic assays.
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MethylationIntroduction
Nearly 50% of adults in the United States have experi-
enced a mood or anxiety disorder at some point in their
lives. Mood and anxiety disorders are among the most de-
bilitating diseases worldwide—the World Health Organi-
zation’s latest Global Burden of Disease report ranked
depression among the top three most prevalent causes of
disability globally, accounting for the highest single pro-
portion of years lived with disability around the world
[1,2]. Panic disorder, as well as self-inflicted injury, which
is often precipitated by depression, were also high on the
WHO list [2]. Mood, anxiety disorders and self-inflicted
injury are also profoundly expensive, imposing high direct* Correspondence: ame2145@columbia.edu
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reproduction in any medium, provided the orand indirect costs on individuals, industry, and health sys-
tems, alike [3].
The search for causes of common mood and anxiety
disorders and suicide has spanned at least a century of
research in a wide range of disciplines. However, a gap
remains between studies focused on exogenous environ-
mental determinants such as negative life events [4] or
neighborhood social context [5,6] and studies focused
on genetic determinants and biological correlates such
as abnormalities in brain circuitry [7]. The recent growth
in interest in epigenetic studies in human populations
has been fueled, in part, by the potential of epigenetics
to bridge this divide [8].
Epigenetic modifications are those reversible, mitotically
heritable alterations in genomic expression that occur in-
dependent of changes in gene sequence [9]. Rather they
occur via methylation of DNA or alterations to chromatin
structure that either impede or facilitate access to thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9]. Epigenetic modification of expression has been
demonstrated to mediate the interplay between environ-
mental stimuli and physiologic—and pathophysiologic—
change throughout the life course [10]. Early research has
been promising [11], demonstrating epigenetic involve-
ment in the pathophysiology of depression [12], anxiety
disorders [13], and suicide [14]. However, a central chal-
lenge to understanding the role of epigenetic modifica-
tions in psychopathology is limited access to brain tissue
in extant studies, where inference has been limited to
assessments of epigenetic modification of peripheral tissue
samples which may not be related to pathophysiologic
processes underlying psychopathology.
Given the growing interest in behavioral epigenetics it
appears to be the appropriate time to take stock, and to
synthesize the peer-reviewed literature about epigenetic
modification in the etiology of common mood and anx-
iety disorder and suicide. In reviewing the existing litera-
ture, we aimed to summarize the state of the science,
identify methodological challenges, and offer potential
solutions to address these challenges.
Methods
We systematically reviewed the literature about epigen-
etic factors in the etiology of mood and anxiety disorders
and suicide. We restricted our search to English-
language, peer-reviewed articles. Our review encom-
passed the literature published between January 1st, 2001
and December 1st, 2011—we limited our review to the
years following the sequencing of the human genome to
reflect current thinking about the genetics of psycho-
pathology. The literature reviewed here was identified
via the MEDLINE and PSYCHINFO databases.
Our original search yielded 1273 articles, 600 of which
were judged to consider epigenetic factors in the etiology
of mood and anxiety disorders and/or suicide after
screening by title. Another 368 were discarded after
screening by abstract because they did not consider epi-
genetic mechanisms or disease outcomes of interest. Of
the remaining 232, articles were included in the review if
they fulfilled the following criteria:
 Included original data about a n> 1 sample of
human subjects
 Used DSM-III, DSM-IV, or ICD-10 criteria to
classify participants as having common mood or
anxiety disorders (including and limited to PTSD,
GAD, Phobias, Panic Disorder, or Depression) OR
used coroners’ reports to classify cause of death by
self-inflicted injury
 Objectively assessed epigenetic mechanisms relating
to the etiology of mood and anxiety disorders or
suicideAfter reading the complete manuscripts, 211 were
excluded because they did not meet our criteria, above.
This left 21 articles from the original search considered
in this review. Reference lists from these articles were
searched, and yielded no further articles which fulfilled
the inclusion criteria, yielding a final total of 21 articles
reviewed here. Figure 1 shows a flow diagram of our
search strategy.
Because of the diversity of outcomes in which we were
interested, the genetic pathways considered in the extant
literature, and the methods used to both assess for epi-
genetic mechanisms and statistically analyze the find-
ings, a meta-analysis of the results would not have been
appropriate or feasible. For each of the 21 papers, we
extracted the following information: the outcome of
interest; sample population; proportion male; proportion
White; number of cases and controls; loci considered;
tissues sampled; laboratory techniques used; statistical
analyses employed; and summary of the findings.
Results
Table 1 includes a detailed review of each of the studies
included in our review. The majority (12) of the studies
included in the literature considered epigenetic modifi-
cation in the etiology of suicide [14-25]. Five studies
considered epigenetic factors and mood disorders (all
five were concerned with depression) [12,26-29], and the
remaining four studies considered epigenetic factors in
the etiology of anxiety disorders (three considered PTSD
and one considered panic disorder) [13,30-32].
All of the studies concerned with epigenetic factors in
suicide assessed gene expression and methylation profiles
in the post-mortem brains of suicide completers relative
to non-suicide controls [14-25], although one study also
included adjuvant data about methylation profiles in per-
ipheral leukocytes [17]. Among studies regarding epigen-
etic factors in the etiology of depression, one study
assessed methylation and expression profiles in the post-
mortem brain [27], another assessed methylation and ex-
pression of tissue in buccal cells [28], and the remaining
three assessed methylation and expression profiles in
peripheral blood [12,26,29]. All four studies about epi-
genetic mechanisms in anxiety disorders assessed methy-
lation and expression in whole blood [13,30-32].
Epigenetic modifications in the etiology of suicide
There were twelve studies concerned with epigenetic
mechanisms in the etiology of suicide [14-25]. Three
studies assessed epigenetic mechanisms involved in the
expression of Brain Derived Neurotrophic Factor
(BDNF) and its receptor, Tropomyosin-Related Kinase B
(TrkB). In a study of post-mortem brain tissue from 10
suicide completers and 10 controls matched on age, gen-
der, post-mortem interval and brain pH, Ernst and
Pubmed and PSYCHINFO searches: 
English-language, peer-reviewed literature 
January 2001-November 2011, inclusive 
1273 articles 
600 articles 
Screened by title 
673 articles discarded 
232 articles  
Screened by abstract 
368 articles discarded 
Screened for following:  
Included original data about a n>1 sample of human subjects 
Objectively assessed epigenetic mechanisms relating to gene expression 
21 empirical articles concerned with epigenetic factors in the 
etiology of common mood and anxiety disorders and suicide 
211 articles discarded 
21 empirical articles concerned with epigenetic factors in the 
etiology of common mood and anxiety disorders and suicide 
 References screened for inclusion into the final review 
0 articles included 
Figure 1 Review search strategy: Epigenetic modification in the etiology of common mood and anxiety disorders and suicide.
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the TrkB.T1 promoter in the frontal cortices of suicide
completers relative to controls, and that methylation fre-
quency at sites 2 and 5 of the promoter were associated
with lower TrkB.T1 expression. By contrast, Keller and
colleagues [22] demonstrated that no significant differ-
ences in TrkB.T1 methylation in Wernecke’s areas of
suicide completers relative to non-suicide controls.
However, in a 2010 study from the same sample, the
group demonstrated that suicide completers had higher
rates of methylation at BDNF promoter IV than non-
suicide controls, and that BDNF promoter IV methyla-
tion was predictive of lower BDNF mRNA expression in
cases relative to controls [21].
Several studies considered epigenetic modification of
genes involved in amine metabolism in the brain. Three
studies using data from the Quebec Suicide Brain Bank
and non-suicide controls from the same area considered
the role of histone methylation at different locations in
the etiology of suicide with conflicting results. The first
found no association between H3K4me3 methylation at
either spermine synthase (SMS) or spermine oxidase
(SMOX) and suicide [25]. In addition, there was no associ-
ation between methylation at either site and risk of suicide
[25]. Another found higher H3K4me3 methylation levels,
a marker of more open chromatin, at the antizyme 1
(OAZ1) promoter [23]. H3K4me3 methylation was corre-
lated with higher expression of OAZ1 and arginase II
(ARG2). A third study by the same group also concernedwith epigenetic modification of genes involved in amine
metabolism found that spermidine/spermine N1-acet-
yltransferase (SAT1) methylation was not associated
with suicide. Similarly, there was no association between
H3K27me3 methylation and suicide. A fourth study using
post-mortem brain samples of 20 suicide cases and 20 non-
suicide controls from the Geneva Institute for Forensic
Medicine considered methylation of the spermine/spermi-
dine N1-acetyltransferase (SSAT) gene promoter in the
ventral prefrontal cortex in the etiology of suicide and
found no association between methylation and suicide.
One study was concerned with epigenetic modifica-
tions of genes involved in 5-HT metabolism. De Luca
and colleagues studied both the post-mortem brains of
suicide completers as well as peripheral blood methyla-
tion expression profiles of suicide attempters to assess
the role of epigenetic modification of the 5-HT2A C102
in the etiology of suicide [17]. Comparing 10 suicide
completers to non-suicide controls matched on geno-
type, age at death, and previous psychiatric diagnoses,
they found no difference in methylation at C102 in the
dorsolateral pre-frontal cortex [17]. They also compared
methylation profiles at this location in the leukocytes of
both suicide attempters and non-suicide controls all of
whom had a history of bipolar disorder or schizophrenia.
While there were no differences in methylation among
bipolar patients, suicide attempters with schizophrenia
had significantly higher methylation levels at the C102
location [17].
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from several brain regions from 10 suicide completers and
10 non-suicide controls in Budapest to assess the role of
DNA methyltransferase (DNMT) expression and subse-
quent GABAA promoter hypermethylation [15]. They
found differential DNMT expression in the frontopolar
cortices, dorsal vagal complexes, and hippocampi of sui-
cide completers relative to controls, and no difference in
the amygdala. Moreover, DNMT-3B upregulation pre-
dicted hypermethylation of CpG islands 2 and 4 in the
GABAA promoter [15].
One study considered the role of epigenetic regulation
of the neuron-specific glucocorticoid receptor (NR3C1)
in suicide etiology among those with a history of child-
hood abuse [19]. McGowan and colleagues found that in
the hippocampi of post-mortem brain tissue among
patients matched on age, gender and post-mortem inter-
val, suicide completers with a history of child abuse had
higher rates of CpG methylation and lower expression of
NR3C1 mRNA than non-abused suicide completers [19].
There were no differences between non-abused suicide
completers and non-suicide controls [19]. Another study
by the same group also considered the role of epigenetic
modification in the etiology of suicide among those
abused during childhood [14]. They found more heavy
methylation of the rRNA promoter in the hippocampi of
suicide completers relative to non-suicide controls [14].
There was, however, no difference in methylation of the
rRNA promoter in the cerebellum of suicide completers
relative to controls [14].
A final study considered the etiology of suicide among
depressive patients. Klempan and colleagues assessed
differences in methylation and expression of the
oligodendrocyte-specific RNA binding protein (QKI) in
suicide completers with a history of major depression
relative to age-matched non-suicide controls [20]. Al-
though they found that suicide completers had signifi-
cantly lower mRNA levels of QKI in 11 cortical regions
as well as in the amygdala, there were no significant dif-
ferences in methylation levels between suicide comple-
ters and non-suicide controls [20].
Epigenetic modifications in the etiology of mood
disorders
There were five studies concerned with the role of epi-
genetic modification in the etiology of mood disorders—
all five were concerned specifically with depression
[12,26-29]. Two studies were concerned with epigenetic
influences in genes involved in 5-HT metabolism and
depression with mixed results [26,28]. In a study of par-
ticipants in the Iowa Adoption Study, Philibert and col-
leagues assessed the relationship between methylation at
the 5-HT transporter (SLC6A4) in lymphoblasts and
both history of and current major depression—theyfound no association between SLC6A4 methylation or
mRNA expression and either outcome [26]. Another
study assessed the relation between 5-HT transporter pro-
moter methylation in buccal cells and depression in a
nested cohort from the Victorian Adolescent Health Study
in Victoria, Australia. While 5-HT transporter promoter
methylation did not predict depression on its own, there
was a significant interaction between methylation and the
short “s-type” allele in predicting depression.
A study by Alt and colleagues assessed the relationship
between glucocorticoid receptor (GR) promoter methylation
in several regions of the post-mortem brains of depressed
patients relative to non-depressed controls from the Dutch
Brain Bank matched on age, sex, brain weight, post-mortem
delay, and pH of the cerebrospinal fluid [27]. There were no
differences in GR mRNA expression levels by disease status
nor in methylation patterns in any of the brain regions
sampled (amygdala, hippocampus, inferior postulate gyrus,
cingulate gyrus, and nucleus accumbens) [27].
In a study of a Japanese sample of depressed patients
and non-depressed controls recruited from four academic
medical centers, Fuchikami and colleagues assessed the
relation between BDNF promoter methylation in white
blood cells and depression [29]. They found that BDNF
promoter methylation at CpG site 1 was associated with
depression, although there was no association between
CpG methylation at site 4 and the outcome [29].
A final study considered “functional annotation clus-
ters” (FACs) of epigenetic modifications in the whole
blood of a community-based sample in Detroit, MI [12].
The authors found that cases had fewer uniquely
unmethylated and methylated genes than controls, and
that methylation predicted lower gene expression. FACs
associated with multicellular organismal development,
lipoprotein activity, and hydrolase activity were uniquely
unmethylated, while those associated with protease ac-
tivity, metabolic processes, and cell development were
uniquely methylated among depressed subjects [12]. In
controls, FACs involved in brain development, trypto-
phan metabolism, and neuromuscular processes were
uniquely unmethylated, while those involved in signal-
ing, lipocalin, and tissue development were uniquely
methylated [12].
Epigenetic modifications in the etiology of anxiety
disorders
There were four studies that considered epigenetic mechan-
isms in the etiology of anxiety disorders [13,30-32]. Three
studies were concerned with the etiology of post-traumatic
stress disorder (PTSD) [30-32] and one was concerned with
panic disorder [13].
With respect to PTSD, none of the three studies con-
sidered epigenetic modification of one specific gene
pathway. Rather each considered non-specific sets of
Table 1 *Studies about epigenetic modifications involved in the etiology of common mood and anxiety disorders and suicide, January 2010-November 2011
Author (Year) Outcome Sample % Male % White N Cases N Controls
Suicide









McGowan et al., 2008 [14] Completed suicide
following child
abuse
Quebec Suicide Brain Bank matched on age,
gender, and post-mortem interval; 5 cases and
1 control used for RNA expression analyses,
separate 13 cases and 11 controls used for
other analyses
100% 100% 18 12





De Luca et al., 2009 [17] Completed suicide Stanley Medical Research Institute
array collection; suicide and non-suicide
controls matched on genotype,




Suicide attempt 48 schizophrenics (24 suicide attempts
and 24 non-attempters) pooled from




Suicide attempt 57 bipolar subjects (29 suicide attempts
and 28 non-attempters) pooled from




Ernst et al., 2009 [18] Completed suicide Quebec Suicide Brain Bank (28 suicide
completers and 11 controls); matched
on age, postermortem interval, and pH.
Epigenetic analyses performed on 10
subjects with low TrKB expression and
10 matched controls.
100% 100% 10 (of 28 possible) 10 (of 11 possible)
McGowan et al., 2009 [19] Completed suicide
following child
abuse
Quebec Suicide Brain Bank matched on
age, gender, and post-mortem interval
100% 100% 24 (12 with history




Klempan et al., 2009 [20] Completed suicide
among depressive
patients
Quebec Suicide Brain Bank matched on age 100% 100% 16 (4 included in
methylation
analysis)
13 (4 included in
methylation
analysis)





Fiori et al., 2010 [25] Completed suicide Quebec Suicide Brain Bank as well as a
Quebecois sample of healthy controls
100% 100% 10 (of 40 possible) 10 (of 56 possible)
Fiori et al., 2011a [24] Completed suicide Quebec Suicide Brain Bank as well as a
Quebecois sample of healthy controls
100% 100% 10 10
Fiori et al., 2011b [23] Completed suicide Quebec Suicide Brain Bank as well as a
Quebecois sample of healthy controls;
suicide completers selected on over-expression
of AMD1, ARG2, OAZ1, and OAZ2
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Keller et al., 2011
[21]






Philibert et al., 2008
[26]
Major depression Iowa Adoption Study participants 50% 93% 68 (history of MD);
17 (current MD)
124 (no history of
MD); 175 (no
current MD)
Alt et al., 2009 [27] Major Depressive
Disorder
Dutch Brain Bank; Matched on age, sex,







Depression Nested cohort from the Victorian
Adolescent Health Cohort Study, a
population-representative sample of
2032 young Australians in Victoria
55% 96% 25 125
Fuchikami et al.,
2011 [29]
Major depression Japanese sample of DSM-IV criteria
depressed patients and health controls
from four academic medical centers
N/I N/I 20 18




Detroit Neighborhood Health Survey, a
multiethnic representative survey of low-
income neighborhoods in Detroit, MI
40% 14% 33 67
Anxiety Disorders
Elser et al., 2006 [13] Panic disorder N/I N/I N/I 24 N/I




Detroit Neighborhood Health Survey, a
multiethnic representative survey of
low-income neighborhoods in Detroit, MI
40% 14% 27 77




Detroit Neighborhood Health Survey, a
multiethnic representative survey of
low-income neighborhoods in Detroit, MI
40% 14% 27 77





Cohort of African-American pariticipants
recruited at clinical waiting rooms in a
low-income, urban context
63% of cases; 60%
of controls
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Author (Year) Gene (s)/loci Tissue Assay Statistical analysis S mmary
Suicide
Poulter et al., 2008 [15] DNMT mRNA expression in the
frontopolar cortex, hippocampus,






ANOVA and t-tests with
Bonferroni corrections;
chi-square tests
D MT-1 was downregulated, and DNMT-3B was
u regulated among suicide completers relative
t controls in the frontopolar cortex. There was
n association between DNMT expression and
s cide in the amygdala. In the hippocampus,
D MT-1 and 3B were downregulated in suicide
c mpleters relative to controls. DNMT-3B was
e vated in the hypothalamus and the dorsal
v gal complex. CG2 and 4 were hypermethylated
i suicide completers relative to controls in the
G BAa alpha1 subunit, and this was associated
w th DNMT-3b upregulation.










r A promotor was more heavily methylated in
t hippocampus of suicide subjects than of
c ntrols. 21 of 26 sites had higher methylation
f quency in suicide subjects relative to controls
i the hippocampus. These differences were not
o served in the cerebellum.




Pyrosequencing ANOVA and t-tests T ere was no association between promotor
m thylation and suicide.





by TaqMan Assay Q-PCR
independent t-tests N significant difference in methylation levels of
C 02 were found in Brain-tissue between suicide
c mpleters and controls.
5-HT2A C102 allele in the
white blood cells
leukocytes Hpall treatment followed
by TaqMan Assay Q-PCR
independent t-tests,
corrected by Bonferroni
S icide attempters had significantly higher
m thylation of 102 C in peripheral leukocytes
r ative to controls.
5-HT2A C102 allele in the
white blood cells
leukocytes Hpall treatment followed
by TaqMan Assay Q-PCR
independent t-tests,
corrected by Bonferroni
T ere was no significant difference in methylation
o 102 C in the peripheral leukocytes of suicide
a empters and controls.





Q-PCR and Western blot
analysis; HG-U133 plus 2
microarray chip
t-test on mean methylation
at two CpG dinucleotides
T ere was a significant difference in TrKB.T1
e pression among suicide completers and
n n-completers. In suicide completers,
d wnregulation was correlated with methylation
f quency at sites 2 and 5 in the TrKB.T1 promotor.
McGowan et al., 2009 [19] NR3C1 neuron-specific
glucocorticoid receptor







T ere was decreased glucocorticoid receptor
m NA and increased cytosine methylation in
a used suicide completers as compared to
n n-abused completers. There were no
d ferences between non-abused completers
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t-test Suicide completers had significantly lower mRNA
levels of QKI in 11 cortical regions and in the
amygdala. However, there were no significant
differences in methylation levels at the QKI
promotor by suicide status.
Keller et al., 2010 [22] Overall methylation in Wernicke's
area; BDNF promotor region






adjusted for sex and age
BDNF promotor IV methylation was significantly
higher in suicide completers relative to controls.
Higher BDNF methylation was associated with
lower BDNF transcript IV. There was no difference
in genome-wide methylation levels between
suicide completers and controls. In suicide
completers with high methylation levels, there
were lower BDNF mRNA levels.
Fiori et al., 2010 [25] SMS and SMOX promotor region






t-test with correction for
mutliple testing
There were no associations between methylation
at any locus and suicide. Histone H3k27me3
methylation was not associated with suicide.
Fiori et al., 2011a [24] SAT1 promotor in the prefrontal






t-test CpG methylation at the SAT1 promotor was
not associated with suicide, although it did
predict decreased SAT1 expression. Histone
H3k27me3 methylation was not associated
with suicide completion.








Suicide completers had significantly higher
H3Kme3 levels at OAZ1. H3Kme3 was positively
correlated with expression of ARG2 and OAZ1.
Keller et al., 2011
[21]
BDNF receptor (TrkB) in Wernicke's




MassArray t-tests There were no significant differences in TrkB
promotor methylation between suicide completers
and controls. BDNF promotor IV methylation was
significantly higher in suicide completers relative
to controls.
Mood Disorders
Philibert et al., 2008
[26]
5HTT promotor SLC6A4 lymphoblast RT-PCR; MassArray quantitative
methylation
ANOVA and linear regression
with Bonferroni corrections
There was no relationship between methylation
and mRNA expression overall. There was no
relationship between SLC6A4 expression and life
history of MD or current MD.
Alt et al., 2009 [27] Glucocorticoid receptor promotor
region (1 J, 1E, 1B, 1 F) of amygdala,
hippocampus, inferior postulate gyrus,
cingulate gyrus, nucleus accumbens
post-mortem
brain




GR transcript levels were homogenous by disease
status. Exon 1 F expression was reduced among
MDD patients relative to controls. There were no
significant differences in methylation patterns
between groups between different brain regions.
Olsson et al.,
2010 [28]
5HTT promotor buccal cells MassArrray logistic regression,
Bonferroni corrections
Buccal cell 5HTT methylation and depression were
not associated either over the entire promotor or
in subregions identified by PCA. However, there
was a joint effect of 5HTT methylation and the
































Mean methylation rates of CpG 1 but not 4 at the
BDNF promotor was associated with depression.
Uddin et al., 2011
[12]




tests for overall methylation;
Functional annotation
clustering analyzed via
Wilcoxon test, alpha< 0.01
Cases had fewer uniquely unmethylated and
methylated genes than controls. Methylated
genes were associated with lower gene expression.
FACs associated with multicellular organismal
development, lipoprotein activity, and hydrolase
activity were uniquely unmethylated, while those
associated with protease activity, metabolic
processes, and cell development were uniquely
methylated in cases. In controls, FACs associated
with brain development, tryptophan metabolism,
and neuormuscular processes were uniquely
unmethylated, while those involved in signaling,
lipocalin, and tissue development were uniquely
methylated.
Anxiety Disorders
Elser et al., 2006 [13] NET promotor and exon 9 white blood
cells
CpGenome DNA modification
it and ABI Prism 7700 Sequence
Detection System; chromatin
immunoprecipitation
t-test on mean methylation
in promotor region
There was a significant difference in NET promotor
methylation among patients with panic disorder
relative to healthy controls. Promotor regions were
also enriched with the MeCP2 co-repressor complex.
Uddin et al., 2010
[30]






Wilcoxon test, alpha< 0.01
There was no difference in overall methylation level
among PTSD cases relative to controls, however
the number of uniquely methylated genes did
differ by disease status. Uniquely unmethylated
genes in PTSD cases were associated immune
system involvement, including TLR1, TLR3 (innate
immune system), IL8, LTA, and KLRG-1 (adaptive
immune system).
Uddin et al., 2011
[31]
33 genes previously described in the
literature as associated with PTSD
whole blood HumanMethylation
27 beadchip




adjusted for race, smoking,
gender, age, socioeconomic
status, peripheral cell count,
and medication
Only MAN2C1 methylation interacted with number
of potentially traumatic events to significantly
predict lifetime PTSD. Increases in both factors
were associated with increased lifetime PTSD risk.
Smith et al., 2011
[32]
non-specific whole blood HumanMethylation
27 beadchip
linear mixed model adjusted
for age, sex, and chip effects,
with adjustment for multiple
testing using the false
discovery rate method
Lifetime PTSD was associated with increased
methylation overall. Lifetime PTSD was associated
with increased methylation in TPR, ANXA2, CLEC9A,
ACPT5, and TLR8 compared to controls. CPG site
methylation at BDNF and CXCL1 were associated
with lifetime PTSD. There was no association
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of African-American participants recruited at clinical
waiting rooms in a low income context used linear
mixed models adjusted for age, sex, and assay effects,
found that increased methylation in white blood cells
was associated with lifetime PTSD [32]. Moreover, those
with lifetime PTSD had increased methylation at several
sites, including translocated promoter region (TPR),
annexin 2 (ANXA2), c-type lectin-like receptor 9A
(CLEC9A), testicular acid phosphatase 5 (ACPT5) and
toll-like receptor 8 (TLR8). Methylation at specific CpG
islands in BDNF and chemokine ligand 1 (CXCL1) were
also associated with lifetime PTSD [32]. Another study
by Uddin and colleagues considered unique methylation
and unmethylation by FAC [30] in white blood cells of a
community-based sample in Detroit, MI. There was no
difference in overall methylation levels among PTSD
cases relative to controls, however the number of
uniquely methylated genes did differ among cases and
controls [30]. Uniquely unmethylated genes in PTSD
cases were associated immune system involvement, in-
cluding toll-like receptor 1 (TLR1), toll-like receptor 3
(TLR3) (innate immune system), interleukin 8 (IL8),
lymphotoxin alpha (LTA), and killer cell lectin-like re-
ceptor G1 (KLRG-1) (adaptive immune system) [30].
Another study among the same population demon-
strated effect modification of the relationship between
the number of reported potentially traumatic events and
the degree of mannosidase 2 C1 (MAN2C1) methyla-
tion, such that among those with increased methylation
at MAN2C1 a larger number of potentially traumatic
events was more strongly related to PTSD risk [31].
A fourth study was concerned with the role of epigen-
etic modification of the promoter as well as exon 9 of
the neuroepithelial cell transforming (NET) gene promo-
tor and exon 9 in the etiology of panic disorder [13].
Using peripheral blood, the authors demonstrated a sig-
nificant difference in NET promotor methylation relative
to healthy controls. Moreover, they noted an enrichment
of the MeCP2 co-repressor complex at the promoter
regions of NET among cases relative to controls [13].
Discussion
We systematically reviewed the peer-reviewed literature
about the role of epigenetic modification in the etiology
of common mood and anxiety disorders and suicide.
Twenty-one papers were published between 2001, the
publication of the human genome project, and 2011.
The majority (12) of studies we found were concerned
with evidence of epigenetic changes in the post-mortem
brains of suicide completers, with other studies consid-
ering epigenetic factors in the etiology of depression,
PTSD, and panic disorder. A plurality focused on epi-
genetic regulation of genes involved in amine,glucocorticoid, and serotonin metabolism in the produc-
tion of common mood and anxiety disorders and sui-
cide; studies also considered epigenetic modification of a
diverse array of other genes.
Given the small number of studies, drawing substan-
tive conclusions about how epigenetic modifications in
specific genes may be operating in the etiology of the
diseases in question is not possible at this stage. Our
review occasions a synthesis of methodological limita-
tions of the extant literature and recommendations on
how investigators may best approach this area in future
studies.
Five methodological limitations to this literature
emerge from our review. The first is that studies in this
area have suffered from small sample sizes, the conse-
quences of which include lack of power and increased
false discovery rates. Second, existing studies have been
limited to assessing epigenetic modification in the post-
mortem brain or the peripheral blood following disease
diagnosis, and drawing inference from either tissue type
is problematic. Third, studies have used different tech-
niques to assess epigenetic modifications that may pro-
duce heterogeneous results. Fourth, few studies have
assessed environmental antecedents to epigenetic modi-
fications in extant studies. Fifth, there appears to be lit-
tle consensus regarding genome-wide vs. candidate-
gene approaches.
The first methodological limitation to this literature is
the use of small sample sizes in most studies, a ubiqui-
tous problem in molecular epidemiology [33]. Of the
studies we reviewed, only one included more than fifty
cases (e.g., subjects with the outcome). Compounding
small sample sizes in studies overall, many of the studies
we reviewed limited epigenetic analysis to a subset of
the total study population. Small sample sizes limit study
power, therefore increasing the likelihood of type II error
(e.g., the proportion of false negative findings) [33].
More dangerously, underpowered studies also increase
the “false discovery rate” or the number of significant
findings that fall into type I error (e.g., the proportion of
false positive findings), as demonstrated in Equation 1
[34-36].
FDR ¼ α 1 priorð Þ
α 1 priorð Þ þ power∗prior ð1Þ
^ “prior” indicates the proportion of tested hypotheses
that are actually correct.
In this equation, the false discovery rate (FDR) is in-
versely proportional to power (1-beta), such that low
power also yields high FDR, driving up Type I error.
Therefore, given the small sample sizes employed in the
majority of studies we reviewed, it is likely that the
El-Sayed et al. Biology of Mood & Anxiety Disorders 2012, 2:10 Page 11 of 14
http://www.biolmoodanxietydisord.com/content/2/1/10findings suffer from high proportions of both type I and
type II error.
A second limitation is the use post-mortem brain or
peripheral cell tissues for epigenetic analyses. Seven of
the 21 studies we reviewed analyzed epigenetic modifica-
tion in peripheral blood cells, and one study analyzed
epigenetic modification in buccal mucosa. Although all
human cells carry the full endowment of genetic mater-
ial, cells modify gene expression to efficiently carry out
their diverse functions as they specialize, silencing some
genes while activating others in line with their physio-
logic responsibilities. Epigenetic modification is the
physiologic process by which genes are silenced or
primed for expression [37,38]. The pathophysiology of
mood-anxiety disorders and suicide is localized to the
brain and it remains therefore unclear how gene expres-
sion in peripheral tissues correlates with physiologically
meaningful gene expression in the brain. However, even
epigenetic studies using post-mortem brain tissue have
challenges. Three of the 21 studies we reviewed analyzed
post-mortem brain tissue. While these studies assessed
epigenetic changes in the appropriate organ, assessing
post-mortem brain tissue carries its own challenges. This
is problematic with respect to temporality between ex-
posure and outcome, because post-mortem brains, by
definition, can only be harvested after death, and there-
fore epigenetic modification can only be ascertained
after the occurrence of the outcome. Moreover, death
often involves acidosis, which may contribute to the in-
stability of genetic material [39-41], increasing the likelihood
of misclassifying epigenetic modification and increasing the
chances of spurious findings. Therefore, much more work is
needed to help us understand the physiologic significance of
both peripheral tissue and brain methylation patterns.
A third limitation to the literature is that published
studies used different laboratory techniques to measure
the degree of epigenetic modification. With respect to
DNA methylation alone, there are a number of gene-
specific assays currently in use, including bisulfite reac-
tion based DNA sequencing methods, which include
bisulfite genomic sequencing PCR [42] and/or methyla-
tion specific PCR [43]; genome-wide screens, such as
CpG island microarrays [44] and Restriction Landmark
Genomic Scanning for Methylation (RLGS-M) techni-
ques [45]; and methylated DNA immunoprecipitation
(MeDIP) [46]. There are few studies that have compared
the sensitivity and specificity of each method, although a
recent study compared two bisulfite sequence-based
assays (which are very similar) head-to-head and found
as much as an 18% difference in identification of methy-
lated CpG islands in biological replicates of human em-
bryonic stem cells [47]. To our knowledge, there are no
“gold standard” assays for most epigenetic markers.
Therefore, differential use of assays may present a sourceof misclassification bias in studies, which would ultim-
ately increase the rate of type II error rate in the extant
literature.
Fourth, studies in our review largely failed to assess
the environmental exposures thought to produce epigen-
etic change to begin with. Only three out of 21 of the
studies reviewed here included any assessment of a com-
mon environmental stressor with respect to epigenetic
modifications and their relationship with common mood
and anxiety disorders and suicide [14,19,20]. This is an
important limitation, as there is ample data demonstrat-
ing the importance of environmental stressors in the eti-
ology of these disorders [48]. Without assessing
common environmental stressors antecedent to epigen-
etic modifications, our studies fail to adequately test
dominant hypotheses about the mediating role of epi-
genetic changes between environments and outcomes in
common mood and anxiety disorders and suicide.
The fifth limitation is the lack of consensus regarding
genome-wide vs. candidate-gene approaches in epigen-
etic studies. Three of the studies we reviewed used
genome-wide approaches [12,30,32], while the remaining
18 studies assessed for epigenetic modifications of candi-
date genes. Both approaches have limitations. With re-
spect to genome-wide studies, the analyses (and findings)
are often unfocused. Unlike in genome-wide association
studies, there is no agreed upon method for analysis and
synthesis of data or for adjustment for multiple compari-
sons in genome-wide epigenetic studies. In particular, ap-
propriate adjustment for multiple comparisons can be
problematic, increasing the proportion of false-positive
findings [49]. Candidate-gene approaches benefit from
being hypothesis-driven, and therefore more amenable to
thoughtful, model-based study designs. However, candidate-
gene approaches face their own limitations. Candidate-gene
studies are more likely to yield overall negative results, as
these studies test only one hypothesis, as compared to
genome-wide studies which test more global hypotheses
about the role of epigenetic modification anywhere in the
genome influencing risk for outcomes of interest. As
candidate-gene approaches are more likely to yield negative
overall findings, there is a high probability of publication
bias, whereby the literature about candidate-gene epigenetic
modification is likely to be highly enriched for positive find-
ings [35].
Limitations of the review
The reader should be aware of several limitations when con-
sidering the findings of our systematic review. First, we lim-
ited our review to the published peer-reviewed literature.
Therefore, it is plausible that our selection of studies may
have been subject to a publication bias, affecting the veracity
of our inferences. Second, we organized studies by outcome.
This organizational scheme may have also, in part, shaped
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inferences largely to methodological critiques of the litera-
ture, it is unlikely that either limitation would have had a
substantial influence on our interpretation of our findings.
Third, our review was limited to only the English-language
literature published in journals indexed in two databases. It
is plausible that we may have missed literature about epigen-
etics in relation to common mood and anxiety disorders
and suicide published in other languages or in journals that
were not indexed in MEDLINE or PSYCHINFO. However,
this is less likely, as a detailed search of the citations of
included studies yielded no further studies for inclusion in
the review.
Conclusions
Research into the epigenetic mechanisms that may underlie
common mood and anxiety disorders and suicide has the
potential to unite the heretofore disparate bodies of work
that have characterized the pathophysiology of these disor-
ders and their population causes, respectively. However, at
this nascent stage in the development of this literature,
there are several methodological challenges, discussed
above, that have yet to be addressed. With respect to these
challenges moving forward, studies about the role of epi-
genetic regulation in the etiology of common mood and
anxiety disorders can improve in the following ways.
As sufficient power and small sizes have dogged extant
studies in this area, future studies require larger sample
sizes, maximizing power and minimizing the false dis-
covery rate. Furthermore, systematic comparisons of
assays used to assess epigenetic modifications are needed
as is consensus around what constitute ‘gold standard’
laboratory techniques for assessing epigenetic modifica-
tion. Another challenge to this literature is the validity
of using epigenetic data from peripheral blood, epithelial
tissue, or post-mortem brain specimens. However, given
the obvious limitations to sampling brain tissue in repre-
sentative populations of living subjects, sampling these
tissues may, in the long-term, remain the best available
option. Future work associating epigenetic modifications
with changes in gene expression and correlating epigen-
etic modifications in peripheral tissues with brain func-
tion may offer one way to address these limitations.
Moreover, work in neuroscience to characterize the rela-
tionship between real-time brain imaging studies and
epigenetic modification in brain regions sampled among
patients undergoing neurosurgery, when living-patient
brain samples can be collected, could yield imaging mar-
kers of epigenetic regulation in the brain. These approaches
represent a handful of the many lines of inquiry that could
improve our capacity to assess epigenetic modification in
the brain. Future studies in this area would also do well to
measure epigenetic modification in relation to its environ-
mental antecedents so as to better assess dominanthypotheses about the mediation of the relationship between
environmental exposures and common mood and anxiety
disorders and suicide by epigenetic modification.
Lastly, both genome-wide and candidate gene approaches
have their role in epigenetic analyses. Genome-wide
approaches may be more appropriate for exploratory ana-
lyses [50]. However, candidate gene approaches may be bet-
ter suited for hypothesis-testing regarding the roles of
individual genes or sets of genes hypothesized to function
in a particular way in disease etiology. It is important that
investigators in this area are attuned to the particular
strengths and weakness of each approach so that each is
used appropriately in studies about the role of epigenetics
in the etiology of common mood and anxiety disorders and
suicide.
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